Mr. Honroth will succeed Jim Clemmer, who will depart the Board on November 2, 2026, and will remain in a consulting capacity to ensure a smooth transition.

The appointment follows a Board-led search prioritizing a leader with medical technology experience, a demonstrated track record of commercial execution and operational discipline to build on the Company's Med Tech momentum, advance its transformation, and drive sustainable revenue growth, margin expansion, and long-term shareholder value.

Mr. Honroth brings more than 20 years of medical device and life sciences leadership experience across markets directly aligned with AngioDynamics' portfolio, including cardiovascular, endovascular, urology and oncology. Earlier in his career, he held senior leadership roles at Abbott Vascular, Becton Dickinson, CareFusion, and Boston Scientific. His leadership experience spans both North American and global markets, including responsibility for large-scale commercial organizations and global business operations, providing a proven foundation for advancing the Company's strategic growth and value-creation priorities.

Most recently, he served as Global President, Life Science at Getinge and previously led Getinge's $1.2 billion North American business, where he accelerated growth, delivered sustained revenue gains, and strengthened operational performance through new product development, strategic portfolio management, and disciplined commercial excellence.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.